The US blood supply has never been safer. This level of safety depends on a multifaceted approach including blood donor screening, sensitive infectious disease testing, and good manufacturing practice. However, risks remain for transfusion-transmitted infections due to bacterial contamination of platelets and emerging diseases. Thus, ongoing improvements in screening and testing are required. Newer pathogen reduction technologies have shown promise in further ameliorating the safety of the blood supply.
MussoDRichardVBroultJCao-LormeauVM. Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 2014;54(11):2924–2930.
2.
PerkinsHABuschMP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50(10):2080–2099.
3.
StansburyLGHessJR. Blood transfusion in World War I: the roles of Lawrence Bruce Robertson and Oswald Hope Robertson in the “most important medical advance of the war”. Transfus Med Rev. 2009;23(3):232–236.
4.
AmmannAJCowanMJWaraDW. Acquired immunodeficiency in an infant: possible transmission by means of blood products. Lancet. 1983;1(8331):956–958.
5.
GoodnoughLTBrecherMEKanterMHAuBuchonJP. Transfusion medicine. First of two parts—blood transfusion. N Engl J Med. 1999;340(6):438–447.
6.
StramerSLNotariEPKrysztofDEDoddRY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?Transfusion. 2013;53(10 pt 2):2449–2458.
7.
StramerSLGalelSA. Infectious disease screening. In: FungMK, ed. Technical Manual of the American Association of Blood Banks. 19th ed. Bethesda, MD: AABB Press; 2017:161–205.
8.
KatzLDoddR.Transfusion-transmitted diseases. In: ShazBHHillyerCDRoshalMAbramsCS, eds. Transfusion Medicine and Hemostasis, Clinical and Laboratory Aspects. 2nd ed. Waltham, MA: Elsevier; 2013.
ZiemannMKruegerSMaierABUnmackAGoergSHennigH. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion. 2007;47(11):1972–1983.
12.
StarasSADollardSCRadfordKWFlandersWDPassRFCannonMJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006;43(9):1143–1151.
13.
ThieleTKrugerWZimmermannK. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion. 2011;51(12):2620–2626.
14.
WuYZouSCableR. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion. 2010;50(4):776–786.
15.
VamvakasEC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005;19(3):181–199.
16.
PreiksaitisJK. The cytomegalovirus-”safe” blood product: is leukoreduction equivalent to antibody screening?Transfus Med Rev. 2000;14(2):112–136.
17.
HongHXiaoWLazarusHMGoodCEMaittaRWJacobsMR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127(4):496–502.
18.
DumontLJKleinmanSMurphyJR. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion. 2010;50(3):589–599.
EderAFKennedyJMDyBA; American Red Cross Regional Blood Centers. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross Experience (2004-2006). Transfusion. 2007;47:1134–1142.
21.
Food and Drug Administration. Draft Guidance for Industry: Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion [Monograph on the Internet]. Silver Spring, MD: Center for Biologics Evaluation and Research, Food and Drug Administration; 2016. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM425952.pdf. Accessed January 10, 2018.
22.
LiJWBrecherMEJacobsonJL. Addressing the risk of bacterial contamination in platelets: a hospital economic perspective. Transfusion. 2017;57(10):2321–2328.
23.
DunbarNMDumontLJSzczepiorkowskiZM. How do we implement day 6 and day 7 platelets at a hospital-based transfusion service?Transfusion. 2016;56(6):1262–1266.
24.
HendricksonJEHillyerCD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009;108(3):759–769.
25.
AABB. Standards for Blood Banks and Transfusion Services. 30th ed. Bethesda, MD: AABB Press; 2016.
PatelHSanderBNelderMP. Long-term sequelae of West Nile virus-related illness: a systematic review. Lancet Infect Dis. 2015;15(8):951–959.
28.
ShirleyDTNataroJP. Zika virus infection. Pediatr Clin North Am. 2017;64(4):937–951.
29.
WilliamsonPCLinnenJMKesslerDA. First cases of Zika virus-infected US blood donors outside states with areas of active transmission. Transfusion. 2017;57(3 pt 2):770–778.
30.
ChambersRWFoleyHTSchmidtPJ. Transmission of syphilis by fresh blood components. Transfusion. 1969;9(1):32–34.
31.
CusterBJanssenMPHubbenGVermeulenMvan HulstM. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV. Vox Sang. 2017;112(6):526–534.
32.
MurrayCJEvansDBAcharyaABaltussenRM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–251.
33.
WebertKECsertiCMHannonJ. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev. 2008;22(1):1–34.
34.
IrschJSeghatchianJ. Update on pathogen inactivation treatment of plasma, with the INTERCEPT blood system: current position on methodological, clinical and regulatory aspects. Transfus Apher Sci. 2015;52(2):240–244.
35.
HauserLRoque-AfonsoAMBeylounéA. Hepatitis E transmission by transfusion of intercept blood system-treated plasma. Blood. 2014;123(5):796–797.
36.
SchmidtMHourfarMKSireisW. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains. Transfusion. 2015;55(9):2104–2112.
Kaiser-GuignardJCanelliniGLionNAbonnencMOsselaerJCTissotJD. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev. 2014;28(6):235–241.
39.
CiaravinoVMcCulloughTCiminoG. The role of toxicology assessment in transfusion medicine. Transfusion. 2003;43(10):1481–1492.
40.
HubbardTBackholerLWiltshireMCardiganRAriënsRA. Effects of riboflavin and amotosalen photoactivation systems for pathogen inactivation of fresh-frozen plasma on fibrin clot structure. Transfusion. 2016;56(1):41–48.
41.
LiJde KorteDWoolumMD. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang. 2004;87(2):82–90.
42.
CardoLJSalataJMendezJReddyHGoodrichR. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci. 2007;37(2):131–137.
43.
RentasFHarmanRGomezC. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion. 2007;47(2):240–247.
44.
GoodrichRPEdrichRALiJSeghatchianJ. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006;35(1):5–17.
45.
Perez-PujolSTondaRLozanoM. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005;45(6):911–919.
46.
TonnettiLProctorMCReddyHLGoodrichRPLeibyDA. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion. 2010;50(5):1019–1027.
47.
HerwaldtBLLindenJVBossermanEYoungCOlkowskaDWilsonM. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med. 2011;155(8):509–519.
48.
ProwseCV. Component pathogen inactivation: a critical review. Vox Sang. 2013;104(3):183–199.
49.
AubryMRichardVGreenJBroultJMussoD. Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 2016;56(1):33–40.
50.
ButlerCDoreeCEstcourtLJ. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2013;28(3):CD009072.
51.
AmatoMSchennachHAstlM. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian regional medical centre. Vox Sang. 2017;112(1):47–55.
52.
SalunkheVvan der MeerPFde KorteDSeghatchianJGutiérrezL. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci. 2015;52(1):19–34.
53.
ÁlvarezMLuis-HidalgoMBrachoMA. Transmission of human immunodeficiency virus type-1 by fresh-frozen plasma treated with methylene blue and light. Transfusion. 2016;56(4):831–836.
54.
SeghatchianJTolksdorfF. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system—an update. Transfus Apher Sci. 2012;46(2):221–229.
55.
Canadian Agency for Drugs and Technologies in Health (CADTH). Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis. CADTH Technol Overv. 2010;1(1):e0106.
56.
RiedlerGFHaycoxARDugganAKDakinHA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang. 2003;85(2):88–95.
57.
DeYoung SullivanKVuTRichardsonGCastilloEMartinezF. Evaluating the frequency of vital sign monitoring during blood transfusion: an evidence-based practice initiative. Clin J Oncol Nurs. 2015;19(5):516–520.
SnyderELStramerSLBenjaminRJ. The safety of the blood supply—time to raise the bar. N Engl J Med. 2015;372(20):1882–1885.
60.
CapAPPidcokeHFKeilSD. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion. 2016;56(suppl 1):S6–S15.
